Background
Phase III RCT (Dutch CKVO 95-04/TME Trial). 1,861 patients with resectable rectal cancer. All underwent TME — the first large trial to mandate TME. Randomized to preoperative short-course RT (25 Gy/5 fx) + TME versus TME alone. Long-term results (12-yr) reported by van Gijn 2011.
Interventions and follow up
Arm A: Short-course RT 25 Gy in 5 fractions → TME within 10 day
Arm B: TME surgery alone
Primary endpoint: Local recurrence
mFollow up: 12 year
Arm B: TME surgery alone
Primary endpoint: Local recurrence
mFollow up: 12 year
Results
12-yr local recurrence: 5% vs 11%, P<.0001
12-yr OS: 48% vs 49%, P=.86 — no difference
10-yr cancer-specific survival: 73% vs 70%, P=.32 — no significant difference
12-yr OS: 48% vs 49%, P=.86 — no difference
10-yr cancer-specific survival: 73% vs 70%, P=.32 — no significant difference
Adverse events
Main adverse events: Higher bowel dysfunction, sexual dysfunction, and late complications in RT arm. Anastomotic leakage not significantly different. RT significantly increased bowel dysfunction (soiling, fecal incontinence).
Conclusions
Preoperative short-course RT significantly halved 12-year local recurrence (5% vs 11%) in the context of TME surgery, but provided no OS or cancer-specific survival benefit. With quality TME surgery, local recurrence can be driven very low and OS is not compromised, but RT retains a local control advantage.
Key Limitations
Key Limitations: No OS benefit despite reduced local recurrence — highlighting that systemic failure drives mortality in rectal cancer. Absolute local recurrence rates were already low with TME (11%) — further reduction to 5% may have marginal clinical impact. Higher late toxicity with short-course RT (bowel, sexual dysfunction) must be weighed against modest local recurrence benefit. Tumor-positive circumferential resection margin (CRM) patients benefited most from RT — future studies should focus RT on CRM+ subgroups.
Clinical Context
The Dutch TME trial demonstrated that TME alone achieves good local control, and adding RT provides additional but modest benefit. It sparked debate about whether all patients with resectable rectal cancer require preoperative RT. Current risk-adapted approaches use MRI-based staging: CRM-threatened or T4 tumors receive preoperative CRT/SCRT; good-prognosis T3 tumors with adequate CRM clearance may be managed with TME alone or SCRT. The Stockholm III and Polish trials further tested SCRT vs long-course CRT.
References